Yang M, Baranov E, Li X M, Wang J W, Jiang P, Li L, Moossa A R, Penman S, Hoffman R M
AntiCancer, Inc., 7917 Ostrow Street, San Diego, CA 92111, USA.
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2616-21. doi: 10.1073/pnas.051626698.
The development of drugs for the control of tumor angiogenesis requires a simple, accurate, and economical assay for tumor-induced vascularization. We have adapted the orthotopic implantation model to angiogenesis measurement by using human tumors labeled with Aequorea victoria green fluorescent protein for grafting into nude mice. The nonluminous induced capillaries are clearly visible against the very bright tumor fluorescence examined either intravitally or by whole-body luminance in real time. The orthotopic implantation model of human cancer has been well characterized, and fluorescence shadowing replaces the laborious histological techniques for determining blood vessel density. Intravital images of orthotopically implanted human pancreatic tumors clearly show angiogenic capillaries at both primary and metastatic sites. A quantitative time course of angiogenesis was determined for an orthotopically growing human prostate tumor periodically imaged intravitally in a single nude mouse over a 19-day period. Whole-body optical imaging of tumor angiogenesis was demonstrated by injecting fluorescent Lewis lung carcinoma cells into the s.c. site of the footpad of nude mice. The footpad is relatively transparent, with comparatively few resident blood vessels, allowing quantitative imaging of tumor angiogenesis in the intact animal. Capillary density increased linearly over a 10-day period as determined by whole-body imaging. Similarly, the green fluorescent protein-expressing human breast tumor MDA-MB-435 was orthotopically transplanted to the mouse fat pad, where whole-body optical imaging showed that blood vessel density increased linearly over a 20-week period. These powerful and clinically relevant angiogenesis mouse models can be used for real-time in vivo evaluation of agents inhibiting or promoting tumor angiogenesis in physiological microenvironments.
开发用于控制肿瘤血管生成的药物需要一种简单、准确且经济的肿瘤诱导血管生成检测方法。我们通过将用维多利亚水母绿色荧光蛋白标记的人类肿瘤移植到裸鼠体内,对原位植入模型进行了改进,以用于血管生成测量。在活体观察或实时全身亮度检测中,相对于非常明亮的肿瘤荧光,无荧光的诱导毛细血管清晰可见。人类癌症的原位植入模型已得到充分表征,荧光阴影法取代了繁琐的组织学技术来确定血管密度。原位植入的人类胰腺肿瘤的活体图像清楚地显示了原发和转移部位的血管生成毛细血管。在19天的时间里,对一只裸鼠体内原位生长的人类前列腺肿瘤进行定期活体成像,确定了血管生成的定量时间进程。通过将荧光性刘易斯肺癌细胞注射到裸鼠足垫的皮下部位,展示了肿瘤血管生成的全身光学成像。足垫相对透明,驻留血管较少,允许在完整动物体内对肿瘤血管生成进行定量成像。通过全身成像确定,毛细血管密度在10天内呈线性增加。同样,将表达绿色荧光蛋白的人类乳腺肿瘤MDA-MB-435原位移植到小鼠脂肪垫,全身光学成像显示血管密度在20周内呈线性增加。这些强大且与临床相关的血管生成小鼠模型可用于在生理微环境中对抑制或促进肿瘤血管生成的药物进行实时体内评估。